REFERENCES
1. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13:221-62.
2. Berg S, Stickle H, Rose SJ, Nemec EC. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis. Obes Rev. 2025;26:e13929.
3. Budini B, Luo S, Tam M, et al. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. EClinicalMedicine. 2026;93:103796.
4. Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open. 2025;8:e2457349.
5. Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026;407:2305-18.
6. Aronne LJ, Sattar N, Horn DB, et al. ; SURMOUNT-4 Investigators. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331:38-48.[PMCID:PMC10714284 DOI:10.1001/jama.2023. 24945 PMID:38078870].
7. Wilding JPH, Batterham RL, Davies M, et al. ; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553-64.
8. Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for the maintenance of body weight reduction: rationale, design, and baseline characteristics of SURMOUNT-MAINTAIN. Obesity. 2025;33:1873-85.
9. Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: a post Hoc analysis of the SURMOUNT-4 trial. JAMA Intern Med. 2026;186:157-67.
10. Levi J, Cross S, Ramesh N, Venter F, Hill A. How low could semaglutide prices fall? An analysis of production cost and implications for global access. Obesity. 2026;34:1545-50.
11. Ciudin A, Baker JL, Belančić A, et al. Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update. Nat Med. 2026;32:1962-6.
